๐ข ๐๐จ๐ฆ๐ง ๐๐ก: $ImmunityBio(IBRX.US) ImmunityBio Completes Phase 3 ANKTIVA Trial Database Lock, Targets November Results and Q4 FDA Filing
๐ ๐๐ฒ๐ ๐๐ถ๐ด๐ต๐น๐ถ๐ด๐ต๐๐:โค ๐๐บ๐บ๐๐ป๐ถ๐๐๐๐ถ๐ผ (๐๐๐ฅ๐ซ) completes ๐ค๐จ๐๐๐ง-๐ฎ.๐ฌ๐ฌ๐ฑ Cohort A database lock.โค Trial includes ๐ฏ๐ฒ๐ฒ randomized patients across ๐ญ๐ญ๐ฌ global clinical sites.โค Study compares ๐๐ก๐๐ง๐๐ฉ๐ ๐ฝ๐น๐๐ ๐๐๐ against BCG alone.โค Targets ๐๐๐-๐ป๐ฎรฏ๐๐ฒ non-muscle invasive bladder cancer patients.โค Previous interim analysis demonstrated ๐๐๐ฎ๐๐ถ๐๐๐ถ๐ฐ๐ฎ๐น๐น๐ ๐๐ถ๐ด๐ป๐ถ๐ณ๐ถ๐ฐ๐ฎ๐ป๐๐น๐ longer complete response duration.โค Independent monitoring committee confirmed ๐ป๐ผ ๐ฎ๐ฑ๐ฑ๐ถ๐๐ถ๐ผ๐ป๐ฎ๐น ๐ฒ๐ป๐ฟ๐ผ๐น๐น๐บ๐ฒ๐ป๐ was required.โค Final analysis will evaluate ๐ฐ๐ผ๐บ๐ฝ๐น๐ฒ๐๐ฒ ๐ฟ๐ฒ๐๐ฝ๐ผ๐ป๐๐ฒ ๐ฟ๐ฎ๐๐ฒ๐ and durability.โค ImmunityBio expects ๐๐ผ๐ฝ๐น๐ถ๐ป๐ฒ ๐ฟ๐ฒ๐๐๐น๐๐ in ๐ก๐ผ๐๐ฒ๐บ๐ฏ๐ฒ๐ฟ ๐ฎ๐ฌ๐ฎ๐ฒ.โค Company targets ๐๐๐ ๐๐๐๐ ๐๐๐ฏ๐บ๐ถ๐๐๐ถ๐ผ๐ป in ๐ค๐ฐ ๐ฎ๐ฌ๐ฎ๐ฒ.โค Potential approval could expand ANKTIVA treatment to ๐ฒ๐ฎ๐ฟ๐น๐ถ๐ฒ๐ฟ-๐๐๐ฎ๐ด๐ฒ bladder cancer patients.๐ ๐ช๐ต๐ ๐ง๐ต๐ถ๐ ๐ ๐ฎ๐๐๐ฒ๐ฟ๐:โค Database lock represents a ๐บ๐ฎ๐ท๐ผ๐ฟ ๐ฟ๐ฒ๐ด๐๐น๐ฎ๐๐ผ๐ฟ๐ ๐บ๐ถ๐น๐ฒ๐๐๐ผ๐ป๐ฒ ahead of final analysis.โค Positive results could significantly expand ๐๐ก๐๐ง๐๐ฉ๐'๐ ๐ฎ๐ฑ๐ฑ๐ฟ๐ฒ๐๐๐ฎ๐ฏ๐น๐ฒ ๐ฝ๐ฎ๐๐ถ๐ฒ๐ป๐ ๐ฝ๐ผ๐ฝ๐๐น๐ฎ๐๐ถ๐ผ๐ป.โค November data and Q4 FDA filing represent ๐ธ๐ฒ๐ ๐ป๐ฒ๐ฎ๐ฟ-๐๐ฒ๐ฟ๐บ ๐ฐ๐ฎ๐๐ฎ๐น๐๐๐๐ for IBRX.โค Final efficacy results remain critical; ๐๐๐ ๐ฎ๐ฝ๐ฝ๐ฟ๐ผ๐๐ฎ๐น ๐ถ๐ ๐ป๐ผ๐ ๐ด๐๐ฎ๐ฟ๐ฎ๐ป๐๐ฒ๐ฒ๐ฑ.๐ ๐๐ ๐ฝ๐ฒ๐ฟ๐ ๐ฆ๐๐ฎ๐๐ฒ๐บ๐ฒ๐ป๐:๐ฃ๐ฎ๐๐ฟ๐ถ๐ฐ๐ธ ๐ฆ๐ผ๐ผ๐ป-๐ฆ๐ต๐ถ๐ผ๐ป๐ด, ๐ .๐., Founder and Executive Chairman of ImmunityBio:"The final analysis of this study will determine whether adding ANKTIVA to BCG improves complete response rates and the durability of those responses when compared with BCG alone,"
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.